Issue date September 2010 (Reviewed October 2013) Clinicians from Andrew Lang Centre, Mental. Specialist Pharmacist & Formulary Pharmacist
|
|
- Noreen Linda Peters
- 6 years ago
- Views:
Transcription
1 Title Document Type Issue no Shared care guidelines in the Treatment of Attention Deficit/ Hyperactivity Disorders Shared Care Guidelines and Information for GPs Clinical Governance Support Team Use Issue date September 2010 (Reviewed October 2013) Review date October 2016 Distribution Prepared by Developed by Equality & Diversity Impact Assessed Posted on NHS Borders intranet Clinicians from Andrew Lang Centre, Mental Health Specialist Pharmacist & Formulary Pharmacist Clinicians from Andrew Lang Centre, Mental Health Specialist Pharmacist & Formulary Pharmcist By development group
2 Shared Care Guidelines and Information for G.P.s Drugs used in the Treatment of Attention Deficit/Hyperactivity Disorders INTRODUCTION Attention Deficit Hyperactivity Disorder (ADHD) is diagnosed if the three main clinical features of inattention, over-activity and impulsivity have been present from an early age, persist in more than one situation (eg at home and at school) and impair function. UK prevalence is 2 to 5% of school age children. The diagnosis is made following a comprehensive assessment by an appropriately trained Child and Adolescent Psychiatrist and/or Paediatrician with a special interest and training in the field. ADHD is often associated with learning difficulties, social difficulties and other medical and psychiatric disorders. Management includes close liaison with other agencies involved as well as behaviour and educational intervention. DRUG TREATMENT Drug treatment will be initiated by the Psychiatrist/Paediatrician following full discussion and agreement with parents or carers and child. (Patient information leaflets given.) The clinical efficacy of drugs used in the treatment of ADHD is very well evidenced and guidelines for their use have been set out in SIGN 112 (Oct 2009) and by NICE 72 (Sep 2008). DRUGS USED Methylphenidate Hydrochloride (drug of first choice) In form of: Methylphenidate (generic)- Available as 5mg, 10mg tablet Equasym XL - A once daily long-acting form. Available in 10mg, 20mg and 30mg capsules Concerta XL - A once daily long acting from. Available in 18mg, 27mg, 36mg capsules Medikinet XL - A once daily long acting form. Available as 5mg, 10mg, 20mg, 30mg, 40 mg capsules Recommended Dosage Dose usually starts at 5mg once or twice daily (or the lowest dose of the long acting preparation advised by the ADHD clinician) and is incrementally increased to achieve maximum response. If no response is achieved within four weeks, the drug is discontinued. Withdrawal should be gradual especially after long term use. A usual maintenance dose is 10-60mg per day depending on age and response. Maximum recommended dose is 2.1mg per kg per day. Total daily dose of 15mg of standard release formulation is considered equivalent to Concerta XL18mg once daily. Effects Dopaminergic effect on the central nervous system, improves concentration and memory. Rapid onset (20-30 minutes), short duration (3-4 hours). Long acting
3 preparations have a slower onset (up to 1 hour) and are effective for up to 8 hours (Equasym XL & Medikinet XL) and 12 hours (Concerta XL). Adverse Effects Precautions and Contra-indications Drug Interactions Controlled Drug Therefore subject to requirements for safe custody and hand written prescriptions stating the quantity to be dispensed in words and figures. It is recommended that 28 days only be prescribed and dispensed. May be a drug of misuse. Not Licensed for use in Children Aged 6 years and under or adults but BNF for children gives a dose for 4-6 years for non MR preparations and used routinely in 5 and 6 year olds. Dexamphetamine Sulphate No longer included in NHS Borders formulary for new starts patients currently stable on dexamfetamine do not require to have their choice of medication changed. Lisdexamfetamine dimesylate Lisdexamfetamine dimesylate is indicated in children aged 6 years of age and over when response to previous methylphenidate treatment is considered clinically inadequate. Effects Lisdexamfetamine dimesylate is a pharmacologically inactive prodrug which is rapidly absorbed from the gastrointestinal tract and hydrolysed primarily by red blood cells to dexamfetamine. Recommended Dosage The starting dose for all patients is 30mg once daily in the morning. This may be increased at approximately weekly intervals by 20mg increments, to a maximum of 70mg once daily. The lowest effective dose should be administered. Treatment should be stopped if the symptoms do not improve after 1 month at an appropriate dose. Adverse Effects Precautions and Contra-indications Drug Interactions Schedule 2 controlled drug.
4 Therefore subject to requirements for safe custody and hand written prescriptions stating the quantity to be dispensed in words and figures. It is recommended that 28 days only be prescribed and dispensed. The SmPC gives details of abuse liability studies which showed that lisdexamfetamine dimesylate has less potential for abuse than dexamfetamine. Atomoxetine Restricted to use in patients who do not respond to stimulants or in whom stimulants are not tolerated or are not clinically appropriate. Effects A selective noradrenaline re-uptake inhibitor. Particularly useful in children with anxiety, tic disorders and Tourettes. Recommended dosage Child over six years and adolescent with body weight up to 70kg, initially 500micrograms/kg daily for seven days, then increased according to response to usual maintenance dose 1.2mg/kg daily. Maximum 1.8mg/kg daily (Max 120mg daily). Child and adolescent with body weight over 70kg, initially 40mg daily for seven days then increased according to response to usual maintenance dose 80mg daily; maximum dose of 120mg daily under specialist direction.. Total daily dose may be given either as a single dose in the morning or in two divided doses with the last dose given no later than early evening. Adverse Effects Precautions and Contra-indications Drug Interactions License for Use For 6-18 year olds only (UK) Atomoxetine is not a stimulant drug (not a controlled drug) and is less likely to be mis-used. Course of ADHD and Arrangements for Transition to Adult Services Approximately 2/3 of young people grow out of the symptoms especially hyperactivity. However, around 1/3 may continue with significant symptoms and are at higher risk of substance mis-use, offending behaviour and emotional and social problems. Most patients will require to continue treatment throughout secondary schooling. At age 18 discussion should take place about the need for continued treatment. If the patient is to continue on treatment they will be referred on to the adult Community Mental Health Team for further management.
5 Shared Care Aspects Psychiatrist/Paediatrician/Prescribing Psychiatric Nurse Responsible for: Assessment and diagnosis of children with ADHD Initial baseline measurement of height, weight, blood pressure and pulse before initiating a trial of medication, and referral on to a paediatrician for medical assessment if previous history or family history of cardiac disease. Decisions on initiating and discontinuing treatment, altering doses and communicating any such changes to GP Monitoring response to treatment, including measuring height, weight and blood pressure (minimum annual review for established cases) Communicating with Primary Care, School Nurse and other involved Services Communicating with GP/Paediatrician about any complications of treatment School Nurse responsible for: Arranging for extra monitoring of weight and height at request of ADHD clinician, if concern about growth. Alert psychiatrist/paediatrician if any concern. General Practitioner Responsible for: Prescribing drug treatment as recommended by Specialist Communicate any new findings or concerns with ADHD clinician. Contact Points 1. Child and Adolescent Mental Health Services Dr Anne-Marie McGhee and Dr Sarah Glen Child and Adolescent Psychiatrists The Andrew Lang Unit Viewfield Lane Selkirk TD7 4LJ Tel: Borders General Hospital Pharmacy Shirley Watson, Clinical Pharmacist Pharmacy Department Borders General Hospital Melrose TD6 9BS Tel: Primary Care Prescribing Team Ros Anderson Senior Pharmacist Medicines Management Pharmacy Department Borders General Hospital Melrose TD6 9BS Tel: Dr Diana Leaver Community Paediatrician Dept of Child Health Borders General Hospital Melrose TD6 9BS Tel:
6 Appendix 1 Diagnostic criteria for ADHD to assist with referral by General Practitioners (see SIGN Guideline No 112 Oct 2009) The core symptoms of ADHD and HKD (hyperkinetic disorder) comprise developmentally inappropriate levels of: Inattention (difficulty in concentrating) Hyperactivity (disorganised, excessive levels of activity) Impulsive behaviour In order to meet diagnostic criteria it is essential that symptoms: Have their onset before the age of seven years (ADHD) or six years (HKD) Have persisted for at least six months Must be pervasive (present in more than one setting, e.g. at home, at school, socially) Have caused significant functional impairment Are not better accounted for by other mental disorders (e.g. pervasive developmental disorder, schizophrenia, other psychotic disorders, depression or anxiety) Associated morbidity includes educational under-achievement, antisocial behaviour, delinquency and an increased risk of road traffic accidents in adolescence. In addition, there can be a dramatic effect on family life. The diagnostic criteria for ADHD and HKD have changed with each revision of the Diagnostic and Statistical Manual (DSM) and International Classification of Diseases (ICD) respectively. It is likely that there will be further revision of the criteria to address outstanding issues such as subtypes of disorder, age of onset and the applicability of the criteria across the life span. Current DSM-IV and ICD-10 diagnostic criteria are similar, with differences relating primarily to symptom severity and pervasiveness. DSM identifies three subtypes of ADHD: Predominantly inattentive type (which features inattention but not hyperactivity/impulsivity) Predominantly hyperactive-impulse type (which features hyperactivity/impulsivity but not inattention Combined type (which features signs of inattention and hyperactivity/impulsivity). HKD characterises more severe disturbance with significant hyperactivity included as a criterion for diagnosis. DSM and ICD are categorical models and minimum thresholds of presenting symptoms must be present to achieve diagnosis. Children and young people failing to meet the defined criteria of ADHD/HKD may nevertheless be experiencing significant difficulties in day to day life. Despite the immense literature describing the investigation of ADHD and HKD, their precise definitions continue to be debated and their validity as disorders questioned. This has been addressed in a number of ways and there is substantial evidence in support of the above definitions of ADHD, its subtypes and HKD. Evidence for the
7 validity of diagnostic criteria for younger children is beginning to emerge, although the applicability of diagnostic criteria across the age range requires further investigation.
8 Appendix 2 Hypertension in Children (provided by Dr A Duncan) 1. Proper Measurement Ensure paediatric cuffs are available in practices Bladder of cuffs is 2/3 lengths of the upper arm and encircles the arm Korktkoff phases: o K1 is systolic BP o K4 (muffling) is diastolic BP in children 12 years and younger o K5 (disappearance) is diastolic BP in children older than 12 years Children should sit; infants should be supine Right arm at level of heart Inflate 20mmHg above point where the radial pulse disappears Circadium rhythm; nadir of BP early morning hours and peak in the afternoon 2. Definition of Hypertension Significant Hypertension Age Systolic Diastolic 0-7 days > days >103 Infant (<2yr) >111 > yrs >115 > yrs >121 > yrs >125 > yrs >135 > yrs >141 >91 An unacceptable drug-induced rise in blood pressure would be a 20% or greater increase above baseline. Adapted from the Task Force on Blood Pressure Control in Children Report of the Second Task Force on Blood Pressure Control in Children Paediatrics 79:1-25 (1987) Revised: October 2013 For Review: October Lead clinician ADHD (CAMHS).
METHYLPHENIDATE AND ATOMOXETINE TREATMENT OF ATTENTION DEFICIT HYPERACTIVITY DISORDER IN CHILDREN AND YOUNG PEOPLE
NOTTINGHAMSHIRE AREA PRESCRIBING COMMITTEE SHARED CARE PROTOCOL AGREEMENT METHYLPHENIDATE AND ATOMOXETINE TREATMENT OF ATTENTION DEFICIT HYPERACTIVITY DISORDER IN CHILDREN AND YOUNG PEOPLE OBJECTIVES To
More informationSHARED PRESCRIBING GUIDELINE
working in partnership with Kingston Richmond Wandsworth SHARED PRESCRIBING GUIDELINE Sutton & Merton Methylphenidate, Dexamfetamine and Atomoxetine for Attention Deficit Hyperactivity Disorder in patients
More informationMethylphenidate Shared Care Agreement For attention deficit hyperactivity disorder (ADHD) in adults Effective Shared Care Agreement
Methylphenidate Shared Care Agreement For attention deficit hyperactivity disorder (ADHD) in adults Effective Shared Care Agreement Section 1: Shared Care arrangements and responsibilities Section 1.1
More informationCardiff & Vale (C&V) UHB Corporate Medicines Management Group (c MMG) SHARED CARE DRUG: LISDEXAMFETAMINE PROTOCOL NUMBER: CV 57
Cardiff & Vale (C&V) UHB Corporate Medicines Management Group (c MMG) SHARED CARE DRUG: LISDEXAMFETAMINE PROTOCOL NUMBER: CV 57 INDICATION: Attention deficit hyperactivity disorder (ADHD) as part of a
More informationIf a specialist asks a GP to prescribe ADHD medication in relation to this disease, the GP should reply to this request as soon as practicable.
Shared Care Protocol for the Methylphenidate and the Management of Attention Deficit Hyperactivity Disorder (ADHD) for children from 4 years up to 17 years and 364 days 1.0 INTRODUCTION The medical assessment
More informationSHARED CARE PRESCRIBING GUIDELINE
Approval date: September 2018. Document review date: September 2021 or sooner if evidence/practice changes g SHARED CARE PRESCRIBING GUIDELINE Methylphenidate, atomoxetine, lisdexamfetamine, dexamfetamine
More informationMRCPsych Pharmacology of ADHD treatment. Dr Xanthe Barkla, Consultant Child and Adolescent Psychiatrist
MRCPsych Pharmacology of ADHD treatment Dr Xanthe Barkla, Consultant Child and Adolescent Psychiatrist 04 01 17 Curriculum mapping MRCPsych Paper A(ii) covers clinical psychopharmacology MRCPsych Syllabus:
More informationAdult Neurodevelopmental Services. ADHD Shared Protocol
Adult Neurodevelopmental Services ADHD Shared Protocol Issue 1: April 2016 1 2 Adult Neurodevelopmental Service Shared Care Protocol for Adult Attention Deficit Hyperactivity Disorder (ADHD) 1. BACKGROUND
More informationChild and Adolescent Mental Health Services (CAMHS)
Child and Adolescent Mental Health Services (CAMHS) Effective shared care agreement (ESCA) for the treatment of Attention Deficit Hyperactivity Disorder (ADHD) with METHYLPHENIDATE This form must be completed
More informationAttention deficit hyperactivity disorder
Attention deficit hyperactivity disorder Diagnosis and management of ADHD in children, young people and adults Issued: September 2008 last modified: March 2013 NICE clinical guideline 72 guidance.nice.org.uk/cg72
More informationClinical guideline Published: 24 September 2008 nice.org.uk/guidance/cg72
Attention deficit hyperactivity disorder: diagnosis and management Clinical guideline Published: 24 September 2008 nice.org.uk/guidance/cg72 NICE 2018. All rights reserved. Subject to Notice of rights
More informationSHARED CARE GUIDELINE
SHARED CARE GUIDELINE Methylphenidate in the treatment of Attention Deficit Hyperactivity Disorder in Children, Young People and Adults Implementation Date: June 2015 Review Date: June 2017 This guidance
More informationBournemouth, Dorset and Poole Prescribing Forum
SHARED CARE GUIDELINES FOR PRESCRIBING OF METHYLPHENIDATE IN ATTENTION DEFICIT HYPERACTIVITY DISORDER IN CHILDREN INDICATION Methylphenidate is generally regarded as a first line choice of treatment for
More informationPrescribing Framework for Lisdexamfetamine for Attention Deficit Hyperactivity Disorder
Hull & East Riding Prescribing Committee Prescribing Framework for Lisdexamfetamine for Attention Deficit Hyperactivity Disorder Patient s Name:.. NHS Number: Patient s Address:... (Use addressograph sticker)
More informationSHARED CARE PROTOCOL FOR THE PRESCRIBING AND MONITORING OF MEDICINES FOR ATTENTION-DEFICIT HYPERACTIVITY DISORDER (ADHD)
SHARED CARE PROTOCOL FOR THE PRESCRIBING AND MONITORING OF MEDICINES FOR ATTENTION-DEFICIT HYPERACTIVITY DISORDER (ADHD) 1. Introduction This protocol describes how patients prescribed medicines for ADHD
More informationLondon Medicines Information Service
London Medicines Information Service Extended-release methylphenidate a review of the pharmacokinetic profiles available March 2018 First authored by Martin Bradley (martin.bradley@gstt.nhs.uk) May 2016
More informationAtomoxetine Effective Shared Care Agreement For Attention Deficit Hyperactivity Disorder (ADHD)
Atomoxetine Effective Shared Care Agreement For Attention Deficit Hyperactivity Disorder (ADHD) Section 1: Shared Care arrangements and responsibilities Section 1.1 Agreement to transfer of prescribing
More informationAtomoxetine (First known as Tomoxetine) (Adopted by the CCG until review and further notice)
New Medicine Report Document Status Atomoxetine (First known as Tomoxetine) (Adopted by the CCG until review and further notice) Post Suffolk D&TC Traffic Light Decision RED Date of Last Revision 12.07.04
More informationScottish Medicines Consortium
Scottish Medicines Consortium atomoxetine capsules 10 mg to 60 mg (Strattera ) (153/05) Eli Lilly and Company Ltd No. 4 February 2005 The Scottish Medicines Consortium has completed its assessment of the
More informationADHD/Hyperkinetic Disorder for Children & Young People (6-17 years) - Methylphenidate, Atomoxetine, Dexamfetamine and Lisdexamfetamine
DOCUMENT TO BE SCANNED INTO ELECTRONIC RECORDS AS AND FILED IN NOTES Patient Name: Date of Birth: NHS No: Name of Referring Consultant: Contact number: INTRODUCTION Attention Deficit Hyperactivity Disorder
More informationKiran Hewitt Katie Sims. Dr Alex Day. Reviewed By Ozma Tahir Lead Medicines Information and Clinical Economy Pharmacist, BHFT
Prescribing Arrangements for the use of methylphenidate, atomoxetine, lisdexamfetamine and amfetamine in adult ADHD (attention deficit hyperactivity disorder) in Berkshire For all referrals of adults with
More informationADHD. Medicines to help symptoms of adult attention deficit hyperactivity disorder (ADHD)
ADHD Medicines to help symptoms of adult attention deficit hyperactivity disorder (ADHD) This guide can help you to make a more informed choice about which medication may be best for you if you have been
More informationPrescribing Framework for Methylphenidate for Attention Deficit Hyperactive Disorder
Hull & East Riding Prescribing Committee Prescribing Framework for Methylphenidate for Attention Deficit Hyperactive Disorder Patient s Name:.. NHS Number: Patient s Address:... (Use addressograph sticker)
More informationDiagnosis and management of ADHD in children, young people and adults
Issue date: September 2008 Attention deficit hyperactivity disorder Diagnosis and management of ADHD in children, young people and adults NICE clinical guideline 72 Developed by the National Collaborating
More informationAn Overview of the ADHD Pathway for Adults in Devon/Torbay
An Overview of the ADHD Pathway for Adults in Devon/Torbay Andrew Blewett, also Charles Antwi, Mark Jay, Ruth Marlow, Rachel Pebworth, Abbie Turner, Rachel Webb January 2016 Resource/capacity 0.8 clinical
More informationBournemouth, Dorset and Poole Prescribing Forum
SHARED CARE GUIDELINE FOR THE USE OF ATOMOXETINE IN ADULTS WITH ATTENTION DEFICIT HYPERACTIVITY DISORDER INDICATION Atomoxetine is a non-stimulant non-amphetamine inhibitor of noradrenaline reuptake. It
More informationPrescribing framework for Dexamfetamine for Attention Deficit Hyperactive Disorder
Hull & East Riding Prescribing Committee Prescribing Framework for Dexamfetamine for Attention Deficit Hyperactive Disorder Patient s Name:.. NHS Number: Patient s Address:... (Use addressograph sticker)
More informationPortsmouth and South East Hampshire Area Prescribing Committee. Shared Care Agreement. Licensed ADHD Medications for the Treatment of Childhood ADHD
Portsmouth and South East Hampshire Area Prescribing Committee Shared Care Agreement Licensed ADHD Medications for the Treatment of Childhood ADHD Produced by: Graham Brown, Children s and Younger Peoples
More informationCardiff & Vale (C&V) UHB Corporate Medicines Management Group (c MMG) SHARED CARE. Drug: METHYLPHENIDATE Protocol number: CV 42
Cardiff & Vale (C&V) UHB Corporate Medicines Management Group (c MMG) SHARED CARE Drug: METHYLPHENIDATE Protocol number: CV 42 Indication: ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD), HYPERKINETIC
More informationTHE SCHOOL SETTING INCLUDING THE ROLE OF COMMUNITY CHILD HEALTH MEDICAL AND SCHOOL NURSING SERVICES
THIS GUIDELINE DESCRIBES THE PHARMACOLOGICAL MANAGEMENT OF Attention Deficit Hyperactivity Disorder IN THE SCHOOL SETTING INCLUDING THE ROLE OF COMMUNITY CHILD HEALTH MEDICAL AND SCHOOL NURSING SERVICES
More informationSHARED CARE AGREEMENT
SHARED CARE AGREEMENT CNS Stimulants and other drugs for Attention Deficit Hyperactivity Disorder (ADHD) in Children (,, hydrochloride) Version: Date: Author: Status: Comment: 6 31.01.2014 Dr Peter Coleman
More informationGREATER MANCHESTER INTERFACE PRESCRIBING GROUP. Replaces: No previous version available. Management Committee 11 th March 2014
GREATER MANCHESTER INTERFACE PRESCRIBING GROUP On behalf of the GREATER MANCHESTER MEDICINES MANAGEMENT GROUP Methylphenidate and Dexamfetamine in children and adolescents: SHARED CARE GUIDELINE Scope:
More informationProtocol 02, v1.0, HMMC October of 22
Protocol 02: Methylphenidate, atomoxetine, dexamfetamine and lisdexamfetamine prescribing and monitoring guidance for treatment of Attention Deficit Hyperactivity Disorder in children, young people and
More informationBNSSG Shared Care Guidance Please complete all sections
NHS Bristol CCG NHS North Somerset CCG NHS South Gloucestershire CCG North Bristol NHS Trust University Hospitals Bristol NHS Foundation Trust Weston Area Health NHS Trust BNSSG Shared Care Guidance Please
More informationPrescribing Framework for Guanfacine Hydrochloride (Intuniv) for Attention Deficit Hyperactivity Disorder
Hull & East Riding Prescribing Committee Prescribing Framework for Guanfacine Hydrochloride (Intuniv) for Attention Deficit Hyperactivity Disorder Patient s Name:.. NHS Number: Patient s Address:... (Use
More informationPrescribing Framework for Dexamfetamine for Attention Deficit Hyperactive Disorder and Narcolepsy
Prescribing Framework for Dexamfetamine for Attention Deficit Hyperactive Disorder and Narcolepsy Patient s Name: NHS Number: Patient s Address: (Use addressograph sticker) GP s Name:... Communication
More informationAppendix 4I - Melatonin Guidance for the treatment of sleep-wake cycle disorders in children
Appendix 4I - Melatonin Guidance for the treatment of sleep-wake cycle disorders in children Background Sleep disturbance in children with neurological or behavioural disorders is common and can be a major
More informationAdult ADHD: How Big is the Problem? Delivering Effective Services for Adults with ADHD
Adult ADHD: How Big is the Problem? Delivering Effective Services for Adults with ADHD North West Mental Health Commissioning Network 1 st March 2016 Dr Prathiba Chitsabesan Consultant Child and Adolescent
More informationSummary of risk management plan for Methylphenidate modifiedrelease hard capsules (methylphenidate)
Part VI: Summary of the risk management plan Summary of risk management plan for Methylphenidate modifiedrelease hard capsules (methylphenidate) This is a summary of the risk management plan (RMP) for
More informationDocument Details Shared Care Agreement Lisdexamfetamine Trust Ref No Local Ref (optional) Main points the document covers
Document Details Title Shared Care Agreement Lisdexamfetamine Trust Ref No 1989-33708 Local Ref (optional) Main points the document covers The responsibilities of each partner entering into the shared
More informationShared Care Guidelines. Shared Care Guidelines for Attention Deficit Hyperactivity Disorder in children:
Shared Care Guidelines Shared Care Guidelines for Attention Deficit Hyperactivity Disorder in children: BACKGROUND Attention Deficit Hyperactivity Disorder (ADHD) is a neuro-developmental condition affecting
More informationNICE guideline Published: 14 March 2018 nice.org.uk/guidance/ng87
Attention deficit hyperactivity disorder: diagnosis and management NICE guideline Published: 14 March 2018 nice.org.uk/guidance/ng87 NICE 2018. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and-conditions#notice-ofrights).
More informationBehavioural Disorders
Behavioural Disorders BEH Hyperkinetic disorder / attention deficit hyperactivity disorder (ADHD) Behavioural disorders is an umbrella term that includes more specific disorders, such as hyperkinetic disorder
More informationAttention Deficit Hyperactivity Disorder
Page 1 of 5 Attention Deficit Hyperactivity Disorder ADHD is a common condition that mainly affects behaviour. Children with this condition show persistent restlessness, impulsiveness and/or inattention.
More informationNHS LINCOLNSHIRE in association with UNITED LINCOLNSHIRE HOSPITALS TRUST AND LINCOLNSHIRE PARTNERSHIP FOUNDATION TRUST
NHS LINCOLNSHIRE in association with UNITED LINCOLNSHIRE HOSPITALS TRUST AND LINCOLNSHIRE PARTNERSHIP FOUNDATION TRUST SHARED CARE GUIDELINE: Methylphenidate, atomoxetine, dexamfetamine and lisdexamfetamine
More informationWorcestershire Area Prescribing Committee Guideline
Worcestershire Area Prescribing Committee Guideline Attention Deficit Hyperactivity Disorder (ADHD) in Adults, Adolescents and Children Prescribing Guidelines and Shared Care for GPs, locum doctors and
More informationShared Care Framework for Dexamfetamine the treatment of ADHD in Adults Date approved by Joint Medicines Operational Group 1/12/17
This policy statement is approved by Southport and Formby, and South Sefton CCGs Southport and Formby South Sefton Shared Care Framework for Dexamfetamine the treatment of ADHD in Adults Date approved
More informationNATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE SCOPE
NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE 1 Guideline title SCOPE Personality disorder: the management and prevention of antisocial (dissocial) personality disorder 1.1 Short title Antisocial
More informationClick on the following link for SEPT prescribing guidelines on ADHD:-
Bedfordshire and Luton Shared care guideline for the use of methylphenidate, dexamfetamine, lisdexamfetamine dimesylate & atomoxetine for the management of Attention-deficit hyperactivity disorder (ADHD)
More informationSHARED CARE GUIDELINE
SHARED CARE GUIDELINE Shared Care Guideline for the treatment of Tourette s Syndrome and other tic disorders in children and adolescents. Scope: Version: Pennine Care NHS Foundation Trust NHS Bury NHS
More informationVersion Control Summary Version Date Comments / changes 1.0 June November January 2009
Document Control Summary Title Purpose of document Electronic file reference (authors) Electronic file reference (network or intranet) Status Draft 4 Version 1 Author(s) Name and position Circulated to
More informationNATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE SCOPE. Personality Disorder: the clinical management of borderline personality disorder
NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE 1 Guideline title SCOPE Personality Disorder: the clinical management of borderline personality disorder 1.1 Short title Borderline personality disorder
More informationTopic proposal. 1. What is the problem/need for a guideline/clinical scenario?
Topic proposal I understand that this proposal will be retained by the Programme Lead and be made available on the website for time period that the proposal is being considered. Only proposals with a completed
More informationIntelligent Prescribing. Optimizing Medication Treatments in ADHD Dr Dave Coghill
Intelligent Prescribing Optimizing Medication Treatments in ADHD Dr Dave Coghill Source Consultant Advisory Board Stock Equity >$10,000 Speaker Research Lilly X X X Janssen/ McNeil X X X UCB X X Shire
More informationEffective Shared Care Agreement (ESCA) Methylphenidate (from age 6 years) Approved for Solihull locality only.
Effective Shared Care Agreement (ESCA) Methylphenidate (from age 6 years) Approved for Solihull locality only. ESCA: For the treatment of Attention-Deficit/Hyperactivity Disorder (ADHD) as part of a comprehensive
More informationADHD. Treatment of ADHD
Shared care guideline for the use of Methylphenidate, Dexamfetamine, Lisdexamfetamine dimesylate & Atomoxetine for the management of Attention Deficit Hyperactivity Disorder (ADHD) in Adults (18-64years)
More informationLMMG New Medicine Recommendation
LMMG New Medicine Recommendation Lisdexamfetamine (Elvanse ) for the treatment of ADHD in children and young adults LMMG Recommendation: Red (Restricted) Lisdexamfetamine (Elvanse ) is recommended for
More informationAdult ADHD for GPs. Maria Mazfari Associate Nurse Consultant Adult ADHD Tina Profitt Clinical Nurse Specialist Adult ADHD
Adult ADHD for GPs Maria Mazfari Associate Nurse Consultant Adult ADHD Tina Profitt Clinical Nurse Specialist Adult ADHD I m a Believer.. Are You? What is ADHD? ADHD is a valid clinical condition defined
More informationGuidance on Safe Prescribing of Melatonin for Sleep Disorders in Children, Young People and Adults
Guidance on Safe Prescribing of Melatonin for Sleep Disorders in Children, Young People and Adults Ref: PHARM-0025-v3 Status: FINAL Document type: Guidelines Guidance on Safe Prescribing of Melatonin Page
More informationChild/Adolescent Attention-Deficit/Hyperactivity Disorder
Child/Adolescent Attention-Deficit/Hyperactivity Disorder NATIONAL GUIDELINE SUMMARY This evidence-based guideline summary is based on the 202 National Child/Adolescent Attention-Defict/ Hyperactivity
More informationDiagnosis and management of ADHD in children and adults
NEW FROM NICE Diagnosis and management of ADHD in children and adults STEVE CHAPLIN In March, NICE updated its guidance on the diagnosis and management of attention deficit hyperactivity disorder (ADHD)
More informationADHD Training for General Practitioners
ADHD Training for General Practitioners Learning Objectives Understand the stigma surrounding ADHD and develop ability to challenge stigma. Understand your role in the ADHD pathway. Understand what you
More informationADHD and Behavioural Paediatrics. Dr Tsui Kwing Wan Department of Paediatrics and Adolescent Medicine Alice Ho Miu Ling Nethersole Hospital
ADHD and Behavioural Paediatrics Dr Tsui Kwing Wan Department of Paediatrics and Adolescent Medicine Alice Ho Miu Ling Nethersole Hospital DSM V Diagnostic Criteria Inattention and/or Hyperactivity impulsivity
More informationFORMULARY AND PRESCRIBING GUIDELINES FOR CHILDREN AND ADOLESCENTS IN MENTAL HEALTH SERVICES
FORMULARY AND PRESCRIBING GUIDELINES FOR CHILDREN AND ADOLESCENTS IN MENTAL HEALTH SERVICES Version Control Summary Version Date Section(s) Author Comment(s)/Amendments 1 August 2008 All Sections Gbemi
More informationGREATER MANCHESTER INTERFACE PRESCRIBING GROUP
GREATER MANCHESTER INTERFACE PRESCRIBING GROUP On behalf of the GREATER MANCHESTER MEDICINES MANAGEMENT GROUP SHARED CARE GUIDELINE FOR THE PRESCRIBING OF SELECTIVE SEROTONIN REUPTAKE INHIBITORS (SSRIs)
More informationEFFECTIVE SHARED CARE AGREEMENT (ESCA)
WORKING IN PARTNERSHIP WITH EFFECTIVE SHARED CARE AGREEMENT (ESCA) DRUG NAME: LICENSED MEDICATIONS FOR ADHD INDICATION/S COVERED: Attention Deficit Hyperactivity Disorder (ADHD) in Children Coastal West
More informationSHARED CARE GUIDELINE
SHARED CARE GUIDELINE Shared Care Guideline for the prescribing and monitoring of antipsychotics for the treatment of Neurodevelopmental Disorders in children and adolescents. Scope: Version 1 Pennine
More informationAdult ADHD Service Development. Dr Joe Johnson Consultant Psychiatrist Five Boroughs Partnership NHS Trust
Adult ADHD Service Development Dr Joe Johnson Consultant Psychiatrist Five Boroughs Partnership NHS Trust Consultant Psychiatrist in 5BP since 2005 My Background Working both in Community and Prison MH
More informationSummary of the risk management plan (RMP) for Intuniv (guanfacine)
EMA/530486/2015 Summary of the risk management plan (RMP) for Intuniv (guanfacine) This is a summary of the risk management plan (RMP) for Intuniv, which details the measures to be taken in order to ensure
More informationPlease note: Although some of these products are not licensed in adults NICE recommends them as treatment in adults
Methylphenidate, Dexamfetamine, Atomoxetine and Lisdexamphetamine Shared care guideline for the treatment of Attention Deficit Hyperactivity Disorder in children, young people and adults Please note: Although
More informationAnnex I. List of the names, pharmaceutical forms, strengths of the medicinal products, route of administration, applicant in the Member States
Annex I List of the names, pharmaceutical forms, strengths of the medicinal products, route of administration, applicant in the Member States 1 Member State EU/EEA Applicant (Invented) Name Strength Pharmaceutical
More informationAWMSG SECRETARIAT ASSESSMENT REPORT. Lisdexamfetamine dimesylate (Elvanse ) 30 mg, 50 mg and 70 mg capsules. Reference number: 188 FULL SUBMISSION
AWMSG SECRETARIAT ASSESSMENT REPORT Lisdexamfetamine dimesylate (Elvanse ) 30 mg, 50 mg and 70 mg capsules Reference number: 188 FULL SUBMISSION This report has been prepared by the All Wales Therapeutics
More informationPrescribing classification: Amber with shared care. NOTES to the GP
SHARED CARE PRESCRIBING GUIDELINE LICENSED MEDICATIONS FOR THE TREATMENT OF ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD) IN CHILDHOOD NOTE: to be used by practices participating in the locally commissioned
More informationSHARED CARE GUIDELINE
SHARED CARE GUIDELINE Title: Shared Care Guideline for the prescribing and monitoring of Antipsychotics for the treatment of Schizophrenia and psychotic symptoms in children and adolescents Scope: Pennine
More informationConditions affecting children and adolescents
1 Conditions affecting children and adolescents SUMMARY Mental health problems in children are common, affecting up to 1 in 1 of the younger population, depending on age. Given the likely demographic changes
More informationNorth Central London Joint Formulary Committee
North Central London Joint Formulary Committee Shared Care Guideline Methylphenidate (immediate release and long acting), Atomoxetine, Dexamfetamine and Lisdexamfetamine for treatment of Adult Attention
More informationEffective Shared Care Agreement for the treatment of severe motor complications in people with Parkinson Disease with apomorphine (APO-go )
Effective Shared Care Agreement for the treatment of severe motor complications in people with Parkinson Disease with apomorphine (APO-go ) This shared care agreement outlines the ways in which the responsibilities
More informationAtomoxetine (Strattera ) 10 mg, 18 mg, 25 mg, 40 mg, 60 mg, 80 mg and 100 mg hard capsules
AWMSG SECRETARIAT ASSESSMENT REPORT Atomoxetine (Strattera ) 10 mg, 18 mg, 25 mg, 40 mg, 60 mg, 80 mg and 100 mg hard capsules Reference number: 1361 This report has been prepared by the All Wales Therapeutics
More informationNew Jersey Department of Children and Families Policy Manual. Date: Chapter: A Health Services Subchapter: 1 Health Services
New Jersey Department of Children and Families Policy Manual Manual: CP&P Child Protection and Permanency Effective Volume: V Health Date: Chapter: A Health Services 1-11-2017 Subchapter: 1 Health Services
More informationDRUGS FOR ADHD: ADOLESCENTS TO ADULTS
DRUGS FOR ADHD: ADOLESCENTS TO ADULTS DISCLOSURE Natasha Rodney-Cail, Pharmacist, Drug Evaluation Unit Has no conflicts of interest Dr. James Chandler, MD, FRCPC Has no conflicts of interest STEVEN Age
More informationLINCOLNSHIRE CLINICAL COMMISSIONING GROUPS in association with UNITED LINCOLNSHIRE HOSPITALS TRUST AND LINCOLNSHIRE PARTNERSHIP FOUNDATION TRUST
LINCOLNSHIRE CLINICAL COMMISSIONING GROUPS in association with UNITED LINCOLNSHIRE HOSPITALS TRUST AND LINCOLNSHIRE PARTNERSHIP FOUNDATION TRUST SHARED CARE GUIDELINE: Methylphenidate, atomoxetine, dexamfetamine
More informationNICE quality standard for attention deficit hyperactivity disorder (QS39)
QS 39 NICE quality standard for attention deficit hyperactivity disorder (QS39) NICE provided the content for this booklet which is independent of any company or product advertised 2 THE COMMISSIONING
More informationAttention Deficit and Hyperkinetic Disorders in Children and Young People
Scottish Intercollegiate Guidelines Network 52 Attention Deficit and Hyperkinetic Disorders in Children and Young People A national clinical guideline 1 Introduction 1 2 Definitions and concepts 3 3 Assessment
More informationFor children and adolescents and continued prescribing in patients transferred to adult services. For newly diagnosed adults
SHARED CARE PROTOCOL FOR: METHYLPHENIDATE, ATOMOXETINE, LISDEXAMFETAMINE and DEXAMFETAMINE FOR THE TREATMENT OF ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD) For children and adolescents and continued
More informationSHARED CARE AGREEMENT. between. Alder Hey Children's NHSFT and Liverpool CCG
This policy statement is approved by Liverpool CCG Halton Liverpool St Helens Warrington West Lancashire SHARED CARE AGREEMENT between Alder Hey Children's NHSFT and Liverpool CCG Methylphenidate (Ritalin,
More informationAttention Deficit Hyperactivity Disorder (ADHD) in Children under Age 6
in Children under Age 6 Level 0 Conduct comprehensive assessment and provide psychoeducation about ADHD, including clearly defined treatment expectations. Consider co-morbid developmental language disorder,
More informationPHARMACY COVERAGE GUIDELINES ORIGINAL EFFECTIVE DATE: 3/15/18 SECTION: DRUGS LAST REVIEW DATE: 3/15/18 LAST CRITERIA REVISION DATE: ARCHIVE DATE:
DYANAVEL XR (amphetamine) extended-release oral suspension Coverage for services, procedures, medical devices and drugs are dependent upon benefit eligibility as outlined in the member's specific benefit
More informationBHR and Waltham Forest CCG GPs and NELFT Shared Care Guidelines
BHR and Waltham Forest CCG GPs and NELFT Shared Care Guidelines Shared Care Guidelines for the Treatment of Attention Deficit Hyperactivity Disorder (ADHD) in Working Age Adults Methylphenidate (Ritalin,
More informationGuidelines for the Utilization of Psychotropic Medications for Children in Foster Care. Illinois Department of Children and Family Services
Guidelines for the Utilization of Psychotropic Medications for Children in Foster Care Illinois Department of Children and Family Services Introduction With few exceptions, children and adolescents in
More informationConduct Disorder in Children and Young People (CYP 5-18 years of age) RISPERIDONE Effective Shared Care Agreement (ESCA)
E102 Conduct Disorder in Children and Young People (CYP 5-18 years of age) RISPERIDONE Effective Shared Care Agreement (ESCA) Patient details Name: Date of birth: NHS number: Contact details Specialist:
More informationJob Title Name Signature Date. Director of Nursing Angela Wallace Signed Angela Wallace 30/6/2014
PATIENT GROUP DIRECTIONS FOR SUPPLY OF VARENICLINE (CHAMPIX ) BY AUTHORISED COMMUNITY PHARMACISTS WORKING IN FORTH VALLEY Protocol Number 445 Version 1 Date protocol prepared: June 2014 Date protocol due
More informationFORMULARY UPDATES ABUHB s Drug Formulary is at:
Aneurin Bevan University Health Board Medicines & Therapeutics Committee PRESCRIBING enewsletter archive at: http://www.wales.nhs.uk/sites3/page.cfm?orgid=814&pid=48407 Dear Gwent Prescriber At its last
More informationScottish Medicines Consortium
Scottish Medicines Consortium levetiracetam, 250, 500, 750 and 1000mg tablets and levetiracetam oral solution 100mg/ml (Keppra ) No. (394/07) UCB Pharma Limited 10 August 2007 The Scottish Medicines Consortium
More informationDOCUMENT NAME: lisdexamfetamine (Vyvanse ) PAGE: 1 of 5 REFERENCE NUMBER: NH.PMN.36 EFFECTIVE DATE: 02/09
PAGE: 1 of 5 IMPORTANT REMINDER This Clinical Policy has been developed by appropriately experienced and licensed health care professionals based on a thorough review and consideration of generally accepted
More informationADHD Medication Shared Care Agreement
For the Treatment of Attention Deficit Hyperactivity Disorder in children aged 6 years of age and over AREAS OF RESPONSIBILITY FOR THE SHARING OF CARE This shared care agreement outlines suggested ways
More informationGM ADHD Strategic Clinical Network. Training for Specialist ADHD Teams
GM ADHD Strategic Clinical Network Training for Specialist ADHD Teams Learning Objectives Understand the stigma surrounding ADHD and develop ability to challenge stigma.. DSM-5 classification of ADHD ADHD
More informationConsolidated Comprehensive Research Plan: Pharmacologic Treatment of Attention Deficit Hyperactivity Disorder in Adults
FINAL Consolidated Comprehensive Research Plan: Pharmacologic Treatment of Attention Deficit Hyperactivity Disorder in Adults April 29 th, 2015 30 Bond Street, Toronto ON, M5B 1W8 www.odprn.ca info@odprn.ca
More information